3 Reasons to Buy Novo Nordisk Stock

Novo Nordisk shares are down over 60% in 24 months, but the bull case highlights a pipeline that could help it regain GLP-1 share. Key catalysts include Amycretin (phase 3) and UBT251 (promising phase 2 data) alongside the already-likely approval path for CagriSema despite it missing the ~25% mean weight-loss target. On shareholder returns, the stock offers a 3.6% forward dividend yield (vs ~1.1% for the S&P 500) and has a strong dividend growth track record plus an ongoing buyback program, supporting a rebound thesis.

Analysis

The market is still pricing NVO like a deteriorating franchise, but the business model is closer to a long-duration annuity than a one-cycle obesity story. That matters because even modest share stabilization in a chronic-use category can support outsized FCF once manufacturing, SG&A, and DTC spend normalize; the next leg of margin recovery does not require leadership, only no further erosion. The real optionality is that newer programs appear to favor scalability over complexity, which is the lever that can matter most if supply, not efficacy, is the bottleneck.

Second-order, a credible NVO rebound would pressure the ecosystem around branded GLP-1s: Lilly would likely defend share through pricing and promotion, while lower-quality entrants and intermediaries dependent on shortage arbitrage would face margin compression. The near-term stock reaction should be driven more by pipeline credibility than by sell-side commentary. Over 1-3 months, the key catalyst is whether upcoming clinical updates show that NVO can narrow the efficacy/safety gap without sacrificing manufacturability.

Contrarian view: consensus is likely overconfident that Lilly’s lead is structurally unassailable, but also too quick to assume NVO can reclaim leadership on the next readout. The more realistic bull case is valuation recovery plus cash return support, with pipeline upside as a free option. What breaks the thesis is evidence of sustained pricing pressure or another data miss that confirms NVO’s pipeline is still a follower rather than a challenger.

Key Decisions for Investors

• Accumulate NVO only on weakness over the next 4-8 weeks; treat it as a 6-12 month cash-flow recovery trade, not a quick momentum call. Risk/reward improves if the stock remains depressed while dividend/buyback support caps downside.
• Relative-value trade: long NVO / short LLY on a 6-12 month horizon only if the spread continues to price a permanent winner-take-all outcome. Stop the pair if LLY re-accelerates share gains or NVO loses pricing power in the next two quarters.
• If implied volatility is reasonable ahead of the next major pipeline readout, use a NVO call spread rather than outright stock to express the binary upside from a positive efficacy/manufacturing update. This preserves upside while limiting damage from another clinical disappointment.
• Watch list, not a trade yet: monitor IBB/XBI and GLP-1 peer multiples for signs that investors are rotating from single-name dominance narratives to a multi-winner setup. That rotation would support NVO multiple expansion even before fundamentals inflect.